Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis

This publication has 11 references indexed in Scilit:

• Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter
  Urology, 2002
• Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. Range
  Journal of Urology, 2002
• Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. Range
  Journal of Urology, 2002
• Free prostate-specific antigen in serum is becoming more complex
  Urology, 2002
• LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY
  Urologic Clinics of North America, 2001
• “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
  Urology, 2000
• Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
  JAMA, 1998
• A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum
  Urology, 1997
• Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements
  JAMA, 1997
• Longitudinal screening for prostate cancer with prostate-specific antigen
  Published by American Medical Association (AMA) ,1996